Sunday, November 1, 2026

Nio Stock Plummets Over 32% In Past 21 Sessions, Sparking Investor Concerns

ViaNews Editorial Team

January 22, 2024

Nio Stock Plummets Over 32% In Past 21 Sessions, Sparking Investor Concerns

(VIANEWS) -

About Nio

Yearly Analysis

Technical Analysis

Nio Inc. (NIO) has seen its stock value decline significantly in recent months, falling below both its 50-day and 200-day moving averages of EUR7.69 and EUR9.06, indicating a downward trend over both short and long terms. The stock's daily trading volume was reported as 553,911,520, which represents an 8.9% drop from its average trading volume of 562,412,000. This suggests a lack of investor trust or enthusiasm towards this stock. Nio's intraday variation average for the past week, month, and quarter has been negative 4.59%; negative 1.87%; and positive 3.37%, respectively. Its highest amplitude of average volatility over this time frame was 4.59% last week; 3.79% for monthly performance; and 3.37% over quarterly timeframe. Such information on volatility provides investors with valuable insight into both its risks and rewards associated with investing in Nio. Nio's stock appears to be overbought (>=80), suggesting it may be due for a price correction as its share prices have been trading above its historical average levels. Therefore, investors should closely follow these indicators when making informed decisions regarding purchasing, selling, or holding Nio's shares.

Quarter Analysis

This statement indicates that the company's revenue has experienced a substantial 46.6% year-on-year increase, now standing at 54.58 billion for twelve trailing months. Investors should take notice, as this growth indicates expansion and an increase in profits; however, revenue alone does not indicate overall financial health or future prospects of a company; other aspects such as profitability, debt levels and management effectiveness must also be taken into consideration.

Equity Analysis

Nio's trailing twelve months EPS stands at EUR-1.78 based on financial information provided, which indicates a loss of EUR1.78 per share over the last year. Nio's Return on Equity (ROE) for the last twelve months stands at an unfavorable -81.57%, which indicates that their equity investors are making negative returns from investing their equity with them - meaning the company is currently unprofitable and not meeting shareholder returns. Investors should carefully evaluate these financial metrics when assessing Nio's performance and future growth potential. Note, however, that negative EPS or ROE don't always indicate poor investment opportunities - other considerations like growth potential and market position could still play a part.

More news about Nio (NIO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com